Great news, finally.
I was wondering about what numbers we could be seeing with both the Eisai partnership and the ERT partnership.
I understand that there is huge potential here, but it's not as if the company has been profitable, right? How should one think about it?
If we divide those $45 Million from Eisai by 10 years, we're talking about $4,5 Million per year. Let's say that it's all profit and slap a 20x multiple on it. That would mean a AUD$126 Million marketcap. The current marketcap is $206 Million, so Mr Market is ascribing a AUD$80 Million value for the Clinical Trials and Research segments.
Is this too low? The administration costs have been consistently higher (or just a bit lower) than the operating profit from the Clinical Trials segment, so...
If Aducanumab doesn't go forward, should we expect a decline in Clinical Trials revenue?
Cheers
Putting numbers on it
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
-0.100(10.5%) |
Mkt cap ! $145.1M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 83.0¢ | $573.3K | 648.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 86.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.0¢ | 6000 | 1 |
View Market Depth
| Last trade - 15.59pm 02/09/2024 (20 minute delay) ? |
| CGS (ASX) Chart |